EGLE ALEXANDER
Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center
Publications
|
Researcher Profile
225 Publications
2023
Journal Articles
Myeloid NGS Analyses of Paired Samples from Bone Marrow and Peripheral Blood Yield Concordant Results: A Prospective Cohort Analysis of the AGMT Study Group
Jansko-Gadermeir, B; Leisch, M; Gassner, FJ; Zaborsky, N; Dillinger, T; Hutter, S; Risch, A; Melchardt, T; Egle, A; Drost, M; Larcher-Senn, J; Greil, R; Pleyer, L
CANCERS. 2023; 15(8): 2305
Full papers/articles (Journal)
How I treat diffuse large B-cell lymphoma.
Melchardt, T; Egle, A; Greil, R;
ESMO Open. 2023; 8(1):100750
Reviews
Health-Related Quality of Life as Assessed by the EQ-5D-5L Predicts Outcomes of Patients Treated with Azacitidine-A Prospective Cohort Study by the AGMT.
Pleyer, L; Heibl, S; Tinchon, C; Vallet, S; Schreder, M; Melchardt, T; Stute, N; Föhrenbach Quiroz, KT; Leisch, M; Egle, A; Scagnetti, L; Wolf, D; Beswick, R; Drost, M; Larcher-Senn, J; Grochtdreis, T; Vaisband, M; Hasenauer, J; Zaborsky, N; Greil, R; Stauder, R;
Cancers (Basel). 2023; 15(5):
Full papers/articles (Journal)
2022
Journal Articles
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.
Ader, F; Bouscambert-Duchamp, M; Hites, M; Peiffer-Smadja, N; Poissy, J; Belhadi, D; Diallo, A; Lê, MP; Peytavin, G; Staub, T; Greil, R; Guedj, J; Paiva, JA; Costagliola, D; Yazdanpanah, Y; Burdet, C; Mentré, F;
Lancet Infect Dis. 2022; 22(2): 209-221.
Full papers/articles (Journal)
– contribution as Studygroup-member
Transcriptomic Profiling Identifies CD8(+ )T Cells in the Brain of Aged and Alzheimer?s Disease Transgenic Mice as Tissue-Resident Memory T Cells
Altendorfer, B; Unger, MS; Poupardin, R; Hoog, A; Asslaber, D; Gratz, IK; Mrowetz, H; Benedetti, A; de Sousa, DMB; Greil, R; Egle, A; Gate, D; Wyss-Coray, T; Aigner, L
J IMMUNOL. 2022; 209(7): 1272-1285.
Full papers/articles (Journal)
Similar But Different: Integrated Phylogenetic Analysis of Austrian and Swiss HIV-1 Sequences Reveal Differences in Transmission Patterns of the Local HIV-1 Epidemics.
Kusejko, K; Tschumi, N; Chaudron, SE; Nguyen, H; Battegay, M; Bernasconi, E; Boni, J; Huber, M; Calmy, A; Cavassini, M; Egle, A; Grabmeier-Pfistershammer, K; Haas, B; Hirsch, H; Klimkait, T; Ollinger, A; Perreau, M; Ramette, A; Flury, BB; Sarcletti, M; Scherrer, A; Schmid, P; Yerly, S; Zangerle, R; Gunthard, HF; Kouyos, RD
JAIDS-J ACQ IMM DEF. 2022; 90(4): e4-e12.
Full papers/articles (Journal)
Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents-A Prospective Cohort Study of the AGMT Study-Group
Leisch, M; Pfeilstocker, M; Stauder, R; Heibl, S; Sill, H; Girschikofsky, M; Stampfl-Mattersberger, M; Tinchon, C; Hartmann, B; Petzer, A; Schreder, M; Kiesl, D; Vallet, S; Egle, A; Melchardt, T; Piringer, G; Zebisch, A; Machherndl-Spandl, S; Wolf, D; Keil, F; Drost, M; Greil, R; Pleyer, L
CANCERS. 2022; 14(10): 2459
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
Randomized Comparison between Krd and Ktd Induction, Followed By K Maintenance or Control in Transplant NonEligible Patients with NDMM: Efficacy and Qol Data (AGMT-MM02 Trial)
Ludwig, H; Melchardt, T; Sormann, S; Zojer, N; Andel, J; Hartmann, BL; Tinchon, C; Gunsilius, E; Podar, K; Egle, A; Willenbacher, W; Woll, E; Schreder, M; Ruckser, R; Bozic, B; Krauth, MT; Petzer, A; Schmitt, CA; Machherndl-Spandl, S; Agis, H; Fillitz, M; Wang, SY; Knop, S; Kainz, S; Paiva, B; Greil, R
BLOOD. 2022; 140: 10185-10188.
Abstracts (Journal)
Challenges in measuring phosphoproteomics with CyTOF in CLL.
Markus Steiner, Daniela Asslaber, Nadja Zaborsky, Alexander Egle, Richard Greil
https://masscytometry2022.de/program. 2022; -5th German Mass Cytometry User Forum; 20.01.-21.01.2022; Online.
Abstracts (Journal)
2021
Journal Articles
RNA editing contributes to epitranscriptome diversity in chronic lymphocytic leukemia.
Gassner, FJ; Zaborsky, N; Buchumenski, I; Levanon, EY; Gatterbauer, M; Schubert, M; Rauscher, S; Hebenstreit, D; Nadeu, F; Campo, E; Egle, A; Greil, R; Geisberger, R
Leukemia. 2021; 35(4):1053-1063
Full papers/articles (Journal)
Vinorelbine as substitute for vincristine in patients with diffuse large B cell lymphoma and vincristine-induced neuropathy.
Hatzl, S; Posch, F; Rezai, A; Gornicec, M; Beham-Schmid, C; Magnes, T; Wagner, S; Deutsch, A; Greinix, H; Uhl, B; Prochazka, KT; Egle, A; Greil, R; Melchardt, T; Linkesch, W; Schulz, E; Neumeister, P;
Support Care Cancer. 2021; 29(9): 519-5207.
Full papers/articles (Journal)
Results of a hospitalization policy of asymptomatic and pre-symptomatic COVID-19-positive long-term care facility residents in the province of Salzburg-a report from the AGMT COVID-19 Registry.
Huemer, F; Rinnerthaler, G; Jörg, B; Morre, P; Stegbuchner, B; Proksch, E; Fleimisch, S; Oberkofler, H; Kremser, I; Greil, R; Egle, A;
Geroscience. 2021; 43(4):-1897
Full papers/articles (Journal)
Myocardial injury in severe COVID-19 is similar to pneumonias of other origin: results from a multicentre study.
Jirak, P; Larbig, R; Shomanova, Z; Fröb, EJ; Dankl, D; Torgersen, C; Frank, N; Mahringer, M; Butkiene, D; Haake, H; Salzer, HJF; Tschoellitsch, T; Lichtenauer, M; Egle, A; Lamprecht, B; Reinecke, H; Hoppe, UC; Pistulli, R; Motloch, LJ;
ESC Heart Fail. 2021; 8(1):37-46
Full papers/articles (Journal)
Two Cases of Pancytopenia with Coombs-Negative Hemolytic Anemia after Chimeric Antigen Receptor T-Cell Therapy.
Kiem, D; Leisch, M; Neureiter, D; Haslauer, T; Egle, A; Melchardt, T; Topp, MS; Greil, R;
Int J Mol Sci. 2021; 22(11):
Case Reports
The Role of Neutrophilic Granulocytes in Philadelphia Chromosome Negative Myeloproliferative Neoplasms.
Kiem, D; Wagner, S; Magnes, T; Egle, A; Greil, R; Melchardt, T;
INT J MOL SCI. 2021; 22(17):
Reviews
A Lower CD4 Count Predicts Most Causes of Death except Cardiovascular Deaths. The Austrian HIV Cohort Study.
Leierer, G; Rieger, A; Schmied, B; Sarcletti, M; Oellinger, A; Wallner, E; Egle, A; Kanatschnig, M; Zoufaly, A; Atzl, M; Rappold, M; El-Khatib, Z; Ledergerber, B; Zangerle, R; Grp
INT J ENV RES PUB HE. 2021; 18(23):
Full papers/articles (Journal)
Spatial Heterogeneity in Large Resected Diffuse Large B-Cell Lymphoma Bulks Analysed by Massively Parallel Sequencing of Multiple Synchronous Biopsies.
Magnes, T; Wagner, S; Thorner, AR; Neureiter, D; Klieser, E; Rinnerthaler, G; Weiss, L; Huemer, F; Schlick, K; Zaborsky, N; Steiner, M; Greil, R; Egle, A; Melchardt, T;
Cancers (Basel). 2021; 13(4):
Full papers/articles (Journal)
Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrence.
Magnes, T; Wagner, S; Thorner, AR; Neureiter, D; Klieser, E; Rinnerthaler, G; Weiss, L; Huemer, F; Zaborsky, N; Steiner, M; Weis, S; Greil, R; Egle, A; Melchardt, T;
ESMO Open. 2021; 6(1): 100012
Full papers/articles (Journal)
Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone : Analysis of the Austrian head and neck cancer registry of the AGMT.
Magnes, T; Wagner, SM; Melchardt, T; Weiss, L; Rinnerthaler, G; Huemer, F; Kopp, M; Gampenrieder, SP; Mayrbäurl, B; Füreder, T; Lenger, D; Andel, J; Egle, A; Greil, R;
Wien Klin Wochenschr. 2021; 133(21-22):-1136.
Full papers/articles (Journal)
Preparing for future waves and pandemics: a global hospital survey on infection control measures and infection rates in COVID-19.
Matoori, S; Kuritzkes, DR; Goh, Y; Quek, ST; Wang, L; Sun, Z; di Marco, F; Borleri, D; Buoro, S; Fagiuoli, S; Ferrari, T; Rizzi, M; Raimondi, F; Cesa, S; Koh, DM; Froehlich, JM; Janssen, S; Lange, B; Egle, A; Erb, S; Mossdorf, E; Gutzeit, A;
Antimicrob Resist Infect Control. 2021; 10(1): 170
Full papers/articles (Journal)
Anti-coagulation for COVID-19 treatment: both anti-thrombotic and anti-inflammatory?
Paar, V; Wernly, B; Zhou, Z; Motloch, LJ; Hoppe, UC; Egle, A; Lichtenauer, M;
J Thromb Thrombolysis. 2021; 51(1):226-231
Full papers/articles (Journal)
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.
Pan, H; Peto, R; Henao-Restrepo, AM; Preziosi, MP; Sathiyamoorthy, V; Abdool Karim, Q; Alejandria, MM; Hernández García, C; Kieny, MP; Malekzadeh, R; Murthy, S; Reddy, KS; Roses Periago, M; Abi Hanna, P; Ader, F; Al-Bader, AM; Alhasawi, A; Allum, E; Alotaibi, A; Alvarez-Moreno, CA; Appadoo, S; Asiri, A; Aukrust, P; Barratt-Due, A; Bellani, S; Branca, M; Cappel-Porter, HBC; Cerrato, N; Chow, TS; Como, N; Eustace, J; García, PJ; Godbole, S; Gotuzzo, E; Griskevicius, L; Hamra, R; Hassan, M; Hassany, M; Hutton, D; Irmansyah, I; Jancoriene, L; Kirwan, J; Kumar, S; Lennon, P; Lopardo, G; Lydon, P; Magrini, N; Maguire, T; Manevska, S; Manuel, O; McGinty, S; Medina, MT; Mesa Rubio, ML; Miranda-Montoya, MC; Nel, J; Nunes, EP; Perola, M; Portolés, A; Rasmin, MR; Raza, A; Rees, H; Reges, PPS; Rogers, CA; Salami, K; Salvadori, MI; Sinani, N; Sterne, JAC; Stevanovikj, M; Tacconelli, E; Tikkinen, KAO; Trelle, S; Zaid, H; Røttingen, JA; Swaminathan, S;
N Engl J Med. 2021; 384(6): 497-511.
Full papers/articles (Journal)
Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study.
Pleyer, L; Leisch, M; Kourakli, A; Padron, E; Maciejewski, JP; Xicoy Cirici, B; Kaivers, J; Ungerstedt, J; Heibl, S; Patiou, P; Hunter, AM; Mora, E; Geissler, K; Dimou, M; Jimenez Lorenzo, MJ; Melchardt, T; Egle, A; Viniou, AN; Patel, BJ; Arnan, M; Valent, P; Roubakis, C; Bernal Del Castillo, T; Galanopoulos, A; Calabuig Muñoz, M; Bonadies, N; Medina de Almeida, A; Cermak, J; Jerez, A; Montoro, MJ; Cortés, A; Avendaño Pita, A; Lopez Andrade, B; Hellstroem-Lindberg, E; Germing, U; Sekeres, MA; List, AF; Symeonidis, A; Sanz, GF; Larcher-Senn, J; Greil, R;
Lancet Haematol. 2021; 8(2): e135-e148.
Full papers/articles (Journal)
Evaluation of circulating cell-free KRAS mutational status as a molecular monitoring tool in patients with pancreatic cancer.
Schlick, K; Markus, S; Huemer, F; Ratzinger, L; Zaborsky, N; Clemens, H; Neureiter, D; Neumayer, B; Beate, AS; Florian, S; Martin, V; Grundbichler, M; Weiss, L; Melchardt, T; Greil, R; Egle, A;
Pancreatology. 2021; 21(8):1466-1471
Full papers/articles (Journal)
AID Contributes to Accelerated Disease Progression in the TCL1 Mouse Transplant Model for CLL.
Schubert, M; Gassner, FJ; Huemer, M; Hopner, JP; Akimova, E; Steiner, M; Egle, A; Greil, R; Zaborsky, N; Geisberger, R
CANCERS. 2021; 13(11):
Full papers/articles (Journal)
A POLE Splice Site Deletion Detected in a Patient with Biclonal CLL and Prostate Cancer: A Case Report.
Steiner, M; Gassner, FJ; Parigger, T; Neureiter, D; Egle, A; Geisberger, R; Greil, R; Zaborsky, N;
Int J Mol Sci. 2021; 22(17):
Case Reports
The interrelationship of smoking, CD4+ cell count, viral load and cancer in persons living with HIV.
The RESPOND study group
AIDS. 2021; 35(5): 747-757.
Full papers/articles (Journal)
Protein kinase C-β-dependent changes in the glucose metabolism of bone marrow stromal cells of chronic lymphocytic leukemia.
von Heydebrand, F; Fuchs, M; Kunz, M; Voelkl, S; Kremer, AN; Oostendorp, RAJ; Wilke, J; Leitges, M; Egle, A; Mackensen, A; Lutzny-Geier, G
STEM CELLS. 2021; 39(6): 819-830.
Full papers/articles (Journal)
Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations.
Wierda, WG; Rawstron, A; Cymbalista, F; Badoux, X; Rossi, D; Brown, JR; Egle, A; Abello, V; Ceballos, EC; Herishanu, Y; Mulligan, SP; Niemann, CU; Diong, CP; Soysal, T; Suzuki, R; Tran, HTT; Wu, SJ; Owen, C; Stilgenbauer, S; Ghia, P; Hillmen, P
LEUKEMIA. 2021; 35(11): 3059-3072.
Reviews
Conference papers, proceedings, abstracts
Clinical Presentation of Patients with Adult Late-Onset Telomere Biology Disorders - Results from the Aachen Telomeropathy Registry
Beier, F; Tometten, M; Kirschner, M; Halfmeyer, I; Vieri, M; Kricheldorf, K; Maurer, A; Roeth, A; Platzbecker, U; Radsak, MP; Schafhausen, P; Corbacioglu, S; Hoechsmann, B; Wilk, CM; Hinze, C; Chromik, J; Egle, A; Heuser, M; Kreuter, M; Kurth, I; Koschmieder, S; Panse, J; Meyer, R; Isfort, S; Brummendorf, TH
BLOOD. 2021; 138:
Abstracts (Journal)
Lack of Bmf Facilitates the Selection of Highly Responsive B-Cell Receptor Clones in Chronic Lymphocytic Leukemia
Maeding, N; Asslaber, D; Zaborsky, N; Villunger, A; Greil, R; Egle, A
BLOOD. 2021; 138:
Abstracts (Journal)
Composition of the Immune Environment at Baseline Correlates with Time to Response and Treatment Outcome in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (MM) Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Observation (AGMT_MM 02 Study)
Manrique, I; Greil, R; Andel, J; Sormann, S; Hartmann, BL; Podar, K; Egle, A; Petzer, A; Zojer, N; Gunsilius, E; Ruckser, R; Bozic, B; Schmitt, CA; Machherndl-Spandl, S; Agis, H; Schreder, M; Wang, SY; Willenbacher, W; Krauth, MT; Tinchon, C; Fillitz, M; Melchardt, T; Knop, S; Paiva, B; Ludwig, H
BLOOD. 2021; 138:
Abstracts (Journal)
The EQ-5D-5L Predicts Treatment Outcomes and Provides Added Value to the R-IPSS in Patients with MDS, CMML or AML Treated within the Austrian Azacitidine Registry - a Prospective Cohort Study By the AGMT Study Group
Pleyer, L; Heibl, S; Tinchon, C; Vallet, S; Petricevic, B; Leisch, M; Egle, A; Senn, TM; Grochtdreis, T; Greil, R; Stauder, R
BLOOD. 2021; 138:
Abstracts (Journal)
Peripheral Blood Complete Remission Provides Added Value to the Classical Definition of Morphologic Complete Remission - a Prospective Cohort Study of 1441 Patients with MDS, CMML and AML Treated within the Austrian Azacitidine Registry
Pleyer, L; Pfeilstocker, M; Stauder, R; Heibl, S; Sill, H; Girschikofsky, M; Stampfl-Mattesberger, M; Tinchon, C; Hartmann, B; Petzer, A; Petricevic, B; Schmitt, CA; Vallet, S; Geissler, K; Sperr, WR; Leisch, M; Egle, A; Melchardt, T; Piringer, G; Zebisch, A; Machherndl-Spandl, S; Wolf, D; Keil, F; Angermann, H; Drost, M; Larcher-Senn, J; Greil, R
BLOOD. 2021; 138:
Abstracts (Journal)
2020
Journal Articles
Evaluation of circulating cell-free DNA as a molecular monitoring tool in patients with metastatic cancer.
Hufnagl, C; Leisch, M; Weiss, L; Melchardt, T; Moik, M; Asslaber, D; Roland, G; Steininger, P; Meissnitzer, T; Neureiter, D; Greil, R; Egle, A;
Oncol Lett. 2020; 19(2):-1558.
Full papers/articles (Journal)
Interdisciplinary Model for Scheduling Post-discharge Cardiopulmonary Care of Patients Following Severe and Critical SARS-CoV-2 (Coronavirus) Infection.
Kopp, K; Lichtenauer, M; Motloch, LJ; Hoppe, UC; Egle, A; Salzer, HJF; Lamprecht, B; Tomasits, J; Müller, HM; Dieplinger, A;
Front Cardiovasc Med. 2020; 7:157
Full papers/articles (Journal)
The Effect of
Leeksma, AC; Derks, IAM; Kasem, MH; Kilic, E; de Klein, A; Jager, MJ; van de Loosdrecht, AA; Jansen, JH; Navrkalova, V; Faber, LM; Zaborsky, N; Egle, A; Zenz, T; Pospisilova, S; Abdel-Wahab, O; Kater, AP; Eldering, E
FRONT ONCOL. 2020; 10: 609409
Full papers/articles (Journal)
Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population.
Ludwig, H; Ponisch, W; Knop, S; Egle, A; Hinke, A; Schreder, M; Lechner, D; Hajek, R; Gunsilius, E; Petzer, A; Weisel, K; Niederwieser, D; Einsele, H; Willenbacher, W; Rumpold, H; Pour, L; Jelinek, T; Krenosz, KJ; Meckl, A; Nolte, S; Melchardt, T; Greil, R; Zojer, N
Leuk Lymphoma. 2020; 61(2):377-386
Full papers/articles (Journal)
Correction: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab.
Magnes, T; Melchardt, T; Hufnagl, C; Weiss, L; Mittermair, C; Neureiter, D; Klieser, E; Rinnerthaler, G; Roesch, S; Gaggl, A; Greil, R; Egle, A;
Pharmacogenomics J. 2020; 20(2):350
Corrections
Stromal cell protein kinase C-β inhibition enhances chemosensitivity in B cell malignancies and overcomes drug resistance.
Park, E; Chen, J; Moore, A; Mangolini, M; Santoro, A; Boyd, JR; Schjerven, H; Ecker, V; Buchner, M; Williamson, JC; Lehner, PJ; Gasparoli, L; Williams, O; Bloehdorn, J; Stilgenbauer, S; Leitges, M; Egle, A; Schmidt-Supprian, M; Frietze, S; Ringshausen, I;
Sci Transl Med. 2020; 12(526):
Full papers/articles (Journal)
Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial.
Rinnerthaler, G; Gampenrieder, SP; Hackl, H; Steiner, M; Monzo-Fuentes, C; Melchardt, T; Magnes, T; Huemer, F; Westphal, T; Hufnagl, C; Hauser-Kronberger, C; Egle, A; Greil, R;
J Clin Med. 2020; 9(6):
Full papers/articles (Journal)
TCL1 transgenic mice as a model for CD49d-high chronic lymphocytic leukemia.
Szenes, E; Harzschel, A; Decker, S; Tissino, E; Pischeli, J; Gutjahr, JC; Kissel, S; Pennisi, S; Hopner, JP; Egle, A; Zaborsky, N; Dierks, C; Follo, M; Chigaev, A; Zucchetto, A; Greil, R; Gattei, V; Hartmann, TN
LEUKEMIA. 2020; 34(9): 2498-2502.
Letters
Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas.
Wagner, SM; Melchardt, T; Egle, A; Magnes, T; Skrabs, C; Staber, P; Simonitsch-Klupp, I; Panny, M; Lehner, B; Greil, R; Keil, F; Jäger, U; Sillaber, C;
Eur J Haematol. 2020; 104(3):251-258
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
TCL1 transgenic mice as a model for CD49d-high chronic lymphocytic leukemia
Hartmann, TN; Szenes, E; Polcik, L; Decker, S; Haslauer, T; Pischeli, J; Kissel, S; Hopner, JP; Egle, A; Zaborsky, N; Dierks, C; Greil, R; Gattei, V; Harzschel, A
ONCOL RES TREAT. 2020; 43(SUPPL 4): 70-70.
Abstracts (Journal)
COVID-19 treatment by anti-coagulation: anti-thrombotic and anti-inflammatory?
Paar, V; Wernly, B; Zhou, Z; Motloch, LJ; Hoppe, UC; Egle, A; Lichtenauer, M
WIEN KLIN WOCHENSCHR. 2020; 132: S217-S217.
Abstracts (Journal)
2019
Journal Articles
B-cell-specific IRF4 deletion accelerates chronic lymphocytic leukemia development by enhanced tumor immune evasion.
Asslaber, D; Qi, Y; Maeding, N; Steiner, M; Denk, U; Höpner, JP; Hartmann, TN; Zaborsky, N; Greil, R; Egle, A;
Blood. 2019; 134(20):-1729
Full papers/articles (Journal)
BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF-κB Nuclear Translocation.
Asslaber, D; Wacht, N; Leisch, M; Qi, Y; Maeding, N; Hufnagl, C; Jansko, B; Zaborsky, N; Villunger, A; Hartmann, TN; Greil, R; Egle, A;
Clin Cancer Res. 2019; 25(6):190-1912
Full papers/articles (Journal)
Obituary for Professor Michael Steurer
Egle, A;
MEMO-MAG EUR MED ONC. 2019; 12(2): 103-104.
Biographical-Items
Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial.
Egle, A; Melchardt, T; Obrtlíková, P; Smolej, L; Kozák, T; Steurer, M; Andel, J; Burgstaller, S; Mikušková, E; Gercheva, L; Nösslinger, T; Papajík, T; Ladická, M; Girschikofsky, M; Hrubiško, M; Jäger, U; Voskova, D; Pecherstorfer, M; Králiková, E; Burcoveanu, C; Spasov, E; Petzer, A; Mihaylov, G; Raynov, J; Oexle, H; Zabernigg, A; Flochová, E; Palášthy, S; Stehlíková, O; Doubek, M; Altenhofer, P; Weiss, L; Magnes, T; Pleyer, L; Klingler, A; Mayer, J; Greil, R;
Cancer Med. 2019; 8(4):-1405.
Full papers/articles (Journal)
Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM.
Huemer, F; Melchardt, T; Jansko, B; Wahida, A; Jilg, S; Jost, PJ; Klieser, E; Katja, S; Magnes, T; Pleyer, L; Greil-Ressler, S; Rass, C; Greil, R; Egle, A;
Eur J Haematol. 2019; 102(5): 437-441.
Full papers/articles (Journal)
Plitidepsin: a potential new treatment for relapsed/refractory multiple myeloma.
Leisch, M; Egle, A; Greil, R;
Future Oncol. 2019; 15(2):109-120
Full papers/articles (Journal)
Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma
Ludwig, H; Poenisch, W; Knop, S; Egle, A; Schreder, M; Lechner, D; Hajek, R; Gunsilius, E; Krenosz, KJ; Petzer, A; Weisel, K; Niederwieser, D; Einsele, H; Willenbacher, W; Melchardt, T; Greil, R; Zojer, N
BRIT J CANCER. 2019; 121(9): 751-757.
Full papers/articles (Journal)
C-Reactive Protein and Neutrophil/Lymphocytes Ratio: Prognostic Indicator for Doubling overall survival Prediction in Pancreatic Cancer Patients.
Schlick, K; Magnes, T; Huemer, F; Ratzinger, L; Weiss, L; Pichler, M; Melchardt, T; Greil, R; Egle, A;
J Clin Med. 2019; 8(11):
Full papers/articles (Journal)
Exome sequencing of the TCL1 mouse model for CLL reveals genetic heterogeneity and dynamics during disease development.
Zaborsky, N; Gassner, FJ; Höpner, JP; Schubert, M; Hebenstreit, D; Stark, R; Asslaber, D; Steiner, M; Geisberger, R; Greil, R; Egle, A;
Leukemia. 2019; 33(4):957-968
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
B-cell specific IRF4 deletion accelerates chronic lymphocytic leukemia development by enhancing tumor immune evasion
Asslaber, D; Qi, Y; Maeding, N; Denk, U; Hopner, JP; Hartmann, TN; Zaborsky, N; Greil, R; Egle, A
ONCOL RES TREAT. 2019; 42: 17-18.
Abstracts (Journal)
Unmaintained remission after discontinuation of kinase inhibitor treatment in chronic lymphocytic leukemia: an observational cohort
Egle, A; Jager, U; Skrabs, C; Durig, J; Nosslinger, T; Wanner, D; Steurer, M; Ringshausen, I; Melchardt, T; Greil, R; Ysebaert, L
ONCOL RES TREAT. 2019; 42: 18-18.
Abstracts (Journal)
A 3-gene DNA methylation signature fails to predict response to bevacizumab in metastatic breast cancer patients treated within the TANIA phase III trial
Gampenrieder, S; Angela, R; Rinnerthaler, G; Hackl, H; Steiner, M; Pulverer, W; Weinhaeusel, A; Klinglmayr, E; Karl, T; Ilic, S; Hufnagl, C; Hauser-Kronberger, C; Egle, A; Greil, R
CANCER RES. 2019; 79(4):
Abstracts (Journal)
Similar but different: Using combined phylogenies of Austria and Switzerland reveals differences in transmission patterns of the local HIV-1 epidemics
Kusejko, K; Battegay, M; Bernasconi, E; Boni, J; Calmy, A; Cavassini, M; Egle, A; Grabmeier-Pfistershammer, K; Haas, B; Klimkait, T; Ollinger, A; Perreau, M; Ramette, A; Flury, BB; Sarcletti, M; Scherrer, A; Schmid, P; Yerly, S; Zangerle, R; Gunthard, HF; Kouyos, RD
HIV MED. 2019; 20: 29-29.
Abstracts (Journal)
The hepatitis C continuum of care among HIV-infected individuals in Austria
Rappold, M; Gisinger, M; Chromy, D; Schmied, B; Ollinger, A; Wallner, E; Zoufaly, A; Egle, A; Kanatschnig, M; Zangerle, R
HIV MED. 2019; 20: 193-193.
Abstracts (Journal)
Cardiovascular events are declining in men with HIV aged 50 years or older in Austria
Rappold, M; Kitchen, M; Rieger, A; Schmied, B; Ollinger, A; Egle, A; Wallner, E; Kanatschnig, M; Zoufaly, A; Ledergerber, B; Zangerle, R
HIV MED. 2019; 20: 118-119.
Abstracts (Journal)
2018
Journal Articles
Remission maintenance treatment options in chronic lymphocytic leukemia.
Egle, A; Pleyer, L; Melchardt, T; Hartmann, TN; Greil, R;
Cancer Treat Rev. 2018; 70:56-66
Reviews
Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.
Egle, A; Steurer, M; Melchardt, T; Weiss, L; Gassner, FJ; Zaborsky, N; Geisberger, R; Catakovic, K; Hartmann, TN; Pleyer, L; Voskova, D; Thaler, J; Lang, A; Girschikofsky, M; Petzer, A; Greil, R;
Ann Hematol. 2018; 97(10): 1825-1839.
Full papers/articles (Journal)
Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.
Egle, A; Steurer, M; Melchardt, T; Weiss, L; Gassner, FJ; Zaborsky, N; Geisberger, R; Catakovic, K; Hartmann, TN; Pleyer, L; Voskova, D; Thaler, J; Lang, A; Girschikofsky, M; Petzer, A; Greil, R;
Ann Hematol. 2018; 97(9):1745
Corrections
DNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic Breast Cancer
Gampenrieder, SP; Rinnerthaler, G; Hackl, H; Pulverer, W; Weinhaeusel, A; Ilic, S; Hufnagl, C; Hauser-Kronberger, C; Egle, A; Risch, A; Greil, R
THERANOSTICS. 2018; 8(8): 2278-2288.
Full papers/articles (Journal)
Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemia.
Gutjahr, JC; Szenes, E; Tschech, L; Asslaber, D; Schlederer, M; Roos, S; Yu, X; Girbl, T; Sternberg, C; Egle, A; Aberger, F; Alon, R; Kenner, L; Greil, R; Orian-Rousseau, V; Hartmann, TN;
Blood. 2018; 131(12): 1337-1349.
Full papers/articles (Journal)
Establishment and validation of a novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia.
Huemer, F; Weiss, L; Faber, V; Neureiter, D; Egle, A; Geissler, K; Voskova, D; Zebisch, A; Burgstaller, S; Pichler, A; Stauder, R; Sperr, W; Lang, A; Pfeilstöcker, M; Machherndl-Spandl, S; Stampfl, M; Greil, R; Pleyer, L;
Wien Klin Wochenschr. 2018; 130(3-4): 115-125.
Full papers/articles (Journal)
Casein kinase 1 is a therapeutic target in chronic lymphocytic leukemia.
Janovska, P; Verner, J; Kohoutek, J; Bryjova, L; Gregorova, M; Dzimkova, M; Skabrahova, H; Radaszkiewicz, T; Ovesna, P; Blanarova, OV; Nemcova, T; Hoferova, Z; Vasickova, K; Smyckova, L; Egle, A; Pavlova, S; Poppova, L; Plevova, K; Pospisilova, S; Bryja, V
BLOOD. 2018; 131(11): 1206-1218.
Full papers/articles (Journal)
The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab.
Magnes, T; Melchardt, T; Hufnagl, C; Weiss, L; Mittermair, C; Neureiter, D; Klieser, E; Rinnerthaler, G; Roesch, S; Gaggl, A; Greil, R; Egle, A;
Pharmacogenomics J. 2018; 18(3):-479
Full papers/articles (Journal)
Clonal evolution and heterogeneity in metastatic head and neck cancer-An analysis of the Austrian Study Group of Medical Tumour Therapy study group.
Melchardt, T; Magnes, T; Hufnagl, C; Thorner, AR; Ducar, M; Neureiter, D; Tränkenschuh, W; Klieser, E; Gaggl, A; Rösch, S; Rasp, G; Hartmann, TN; Pleyer, L; Rinnerthaler, G; Weiss, L; Greil, R; Egle, A;
Eur J Cancer. 2018; 93:69-78
Full papers/articles (Journal)
Novel models for prediction of benefit and toxicity with FOLFIRINOX treatment of pancreatic cancer using clinically available parameters.
Schlick, K; Magnes, T; Ratzinger, L; Jaud, B; Weiss, L; Melchardt, T; Greil, R; Egle, A;
PLoS One. 2018; 13(11): e0206688
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
Exome sequencing of tumors from the TCL1 mouse model for CLL reveals genetic heterogeneity and dynamics during disease development
Egle, A; Gassner, FJ; Hopner, JP; Hebenstreit, D; Stark, R; Asslaber, D; Steiner, M; Geisberger, R; Greil, R; Zaborsky, N
ONCOL RES TREAT. 2018; 41: 31-31.
Abstracts (Journal)
Deletion of the p53 Target Gene PUMA Prevents Bone Marrow Failure in a Dyskeratosis Congenita Mouse Model
Erlacher, M; Molnar, C; Weiss, JM; Bohler, S; Steinemann, D; Gohring, G; Villunger, A; Labi, V; Niemeyer, C; Egle, A
BLOOD. 2018; 132:
Abstracts (Journal)
Long-Term Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Polycythemia Vera - Final Phase I/II Peginvera Study Results
Gisslinger, H; Buxhofer-Ausch, V; Thaler, J; Forjan, E; Willenbacher, E; Wolf, D; Kralovics, R; Gisslinger, B; Stampfl-Mattersberger, M; Egle, A; Melchardt, T; Burgstaller, S; Schalling, M; Krauth, MT; Greil, R; Kadlecova, P; Zoerer, M; Empson, V; Grohmann-Izay, B; Klade, C
BLOOD. 2018; 132:
Abstracts (Journal)
Evaluation of circulating cell-free DNA as a molecular monitoring tool in patients with metastatic cancer
Hufnagl, C; Leisch, M; Weiss, L; Melchardt, T; Moik, M; Geisberger, R; Asslaber, D; Steininger, P; Meissnitzer, T; Neureiter, D; Greil, R; Egle, A
ONCOL RES TREAT. 2018; 41: 307-307.
Abstracts (Journal)
The HIV continuum of care in Austria from 2010 to 2016: data and challenges
Leierer, G; van Sighem, A; Rieger, A; Schmied, B; Sarcletti, M; Ollinger, A; Haas, B; Egle, A; Rappold, M; Zangerle, R
J INT AIDS SOC. 2018; 21:
Abstracts (Journal)
Spatial heterogeneity in diffuse large B-cell lymphoma
Magnes, T; Melchardt, T; Thorner, A; Neureiter, D; Klieser, E; Greil, R; Egle, A
ONCOL RES TREAT. 2018; 41: 243-244.
Abstracts (Journal)
2017
Journal Articles
TIGIT expressing CD4+T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia.
Catakovic, K; Gassner, FJ; Ratswohl, C; Zaborsky, N; Rebhandl, S; Schubert, M; Steiner, M; Gutjahr, JC; Pleyer, L; Egle, A; Hartmann, TN; Greil, R; Geisberger, R;
Oncoimmunology. 2017; 7(1):e1371399
Full papers/articles (Journal)
Milestones in Chronic Lymphocytic Leukemia: An exciting decade of progress-10th anniversary of memo.
Egle, A
MEMO-MAG EUR MED ONC. 2017; 10(1): 8-12.
Reviews
Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia : A case report.
Huemer, F; Dejaco, M; Grabmer, C; Melchardt, T; Neureiter, D; Mayer, G; Egle, A; Greil, R; Weiss, L;
Wien Klin Wochenschr. 2017; 129(3-4):-144
Case Reports
Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib.
Kazianka, L; Drucker, C; Skrabs, C; Thomas, W; Melchardt, T; Struve, S; Bergmann, M; Staber, PB; Porpaczy, E; Einberger, C; Heinz, M; Hauswirth, A; Raderer, M; Pabinger, I; Thalhammer, R; Egle, A; Wendtner, CM; Follows, G; Hoermann, G; Quehenberger, P; Jilma, B; Jaeger, U;
Leukemia. 2017; 31(5): 1117-1122.
Full papers/articles (Journal)
A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma.
Kiesewetter, B; Willenbacher, E; Willenbacher, W; Egle, A; Neumeister, P; Voskova, D; Mayerhoefer, ME; Simonitsch-Klupp, I; Melchardt, T; Greil, R; Raderer, M;
Blood. 2017; 129(3):-385
Full papers/articles (Journal)
Red blood cell alloimmunization in 184 patients with myeloid neoplasms treated with azacitidine - A retrospective single center experience.
Leisch, M; Weiss, L; Lindlbauer, N; Jungbauer, C; Egle, A; Rohde, E; Greil, R; Grabmer, C; Pleyer, L;
Leuk Res. 2017; 59:12-19
Full papers/articles (Journal)
Update on squamous cell carcinoma of the head and neck: ASCO annual meeting 2017.
Magnes, T; Egle, A; Greil, R; Melchardt, T;
MEMO-MAG EUR MED ONC. 2017; 10(4): 220-223.
Reviews
Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy.
Magnes, T; Melchardt, T; Weiss, L; Mittermair, C; Neureiter, D; Klieser, E; Gampenrieder, S; Moser, G; Gaggl, A; Greil, R; Egle, A;
PLoS One. 2017; 12(7):e0180995
Full papers/articles (Journal)
Influence of body mass index on survival in indolent and mantle cell lymphomas: analysis of the StiL NHL1 trial.
Weiss, L; Melchardt, T; Egle, A; Hopfinger, G; Hackl, H; Greil, R; Barth, J; Rummel, M;
Ann Hematol. 2017; 96(7): 1155-1162.
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
SUCCESSFUL LONG-TERM MAINTENANCE OF PV PATIENTS WITH A MONTHLY SCHEDULE OF ROPEGINTERFERON ALFA-2B-AN UPDATE FROM THE PEGINVERA STUDY
Buxhofer-Ausch, V; Grohmann-Izay, B; Thaler, J; Schloegl, E; Gastl, G; Wolf, D; Kralovics, R; Gisslinger, B; Ban, S; Egle, A; Melchardt, T; Burgstaller, S; Willenbacher, E; Schalling, M; Krauth, MT; Greil, R; Zoerer, M; Kadlecova, P; Klade, C; Gisslinger, H
HAEMATOLOGICA. 2017; 102: 284-284.
Abstracts (Journal)
Low expression of miR-20a-5p predicts benefit to bevacizumab in metastatic breast cancer patients treated within the TANIA trial
Gampenrieder, SP; Rinnerthaler, G; Hackl, H; Steiner, M; Fuentes, CM; Hufnagl, C; Hauser-Kronberger, C; Egle, A; Greil, R
ANN ONCOL. 2017; 28:
Abstracts (Journal)
Casein Kinase 1 delta/epsilon inhibition blocks CLL chemotaxis and delays leukemia onset in the E mu-TCL1 mouse model of chronic lymphocytic leukemia
Janovska, P; Verner, J; Kohoutek, J; Bryjoval, L; Dzimkova, M; Skabrahova, H; Radaszkiewicz, T; Nemcova, T; Hoferova, Z; Vasickova, K; Smyckova, L; Gregorova, M; Egle, A; Pavlova, S; Poppova, L; Pospisilova, S; Bryja, V
LEUKEMIA LYMPHOMA. 2017; 58: 210-211.
Abstracts (Journal)
2016
Journal Articles
Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.
Greil, R; Obrtlíková, P; Smolej, L; Kozák, T; Steurer, M; Andel, J; Burgstaller, S; Mikušková, E; Gercheva, L; Nösslinger, T; Papajík, T; Ladická, M; Girschikofsky, M; Hrubiško, M; Jäger, U; Fridrik, M; Pecherstorfer, M; Králiková, E; Burcoveanu, C; Spasov, E; Petzer, A; Mihaylov, G; Raynov, J; Oexle, H; Zabernigg, A; Flochová, E; Palášthy, S; Stehlíková, O; Doubek, M; Altenhofer, P; Pleyer, L; Melchardt, T; Klingler, A; Mayer, J; Egle, A;
Lancet Haematol. 2016; 3(7):e317-e329
Full papers/articles (Journal)
Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo.
Hanna, BS; McClanahan, F; Yazdanparast, H; Zaborsky, N; Kalter, V; Rößner, PM; Benner, A; Dürr, C; Egle, A; Gribben, JG; Lichter, P; Seiffert, M;
Leukemia. 2016; 30(3): 570-579.
Full papers/articles (Journal)
The AKT1 isoform plays a dominant role in the survival and chemoresistance of chronic lymphocytic leukaemia cells.
Hofbauer, SW; Krenn, PW; Piñόn Hofbauer, J; Pucher, S; Asslaber, D; Egle, A; Hartmann, TN; Greil, R;
Br J Haematol. 2016; 172(5):815-819
Letters
CD4+ T cells, but not non-classical monocytes, are dispensable for the development of chronic lymphocytic leukemia in the TCL1-tg murine model.
Kocher, T; Asslaber, D; Zaborsky, N; Flenady, S; Denk, U; Reinthaler, P; Ablinger, M; Geisberger, R; Bauer, JW; Seiffert, M; Hartmann, TN; Greil, R; Egle, A; Piñón Hofbauer, J;
Leukemia. 2016; 30(6):1409-1413
Letters
Bcl-2 proteins in development, health, and disease of the hematopoietic system.
Kollek, M; Müller, A; Egle, A; Erlacher, M;
FEBS J. 2016; 283(15): 2779-2810.
Reviews
ILK Induction in Lymphoid Organs by a TNFα-NF-κB-Regulated Pathway Promotes the Development of Chronic Lymphocytic Leukemia.
Krenn, PW; Hofbauer, SW; Pucher, S; Hutterer, E; Hinterseer, E; Denk, U; Asslaber, D; Ganghammer, S; Sternberg, C; Neureiter, D; Aberger, F; Wickström, SA; Egle, A; Greil, R; Hartmann, TN;
Cancer Res. 2016; 76(8):218-296
Full papers/articles (Journal)
Fluorouracil and Dihydropyrimidine Dehydrogenase Genotyping.
Magnes, T; Melchardt, T; Weiss, L; Hufnagl, C; Greil, R; Egle, A;
J Clin Oncol. 2016; 34(20):2433-2434
Letters
Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones.
Melchardt, T; Hufnagl, C; Weinstock, DM; Kopp, N; Neureiter, D; Tränkenschuh, W; Hackl, H; Weiss, L; Rinnerthaler, G; Hartmann, TN; Greil, R; Weigert, O; Egle, A;
Oncotarget. 2016; 7(32):51494-51502
Full papers/articles (Journal)
NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients.
Prochazka, KT; Melchardt, T; Posch, F; Schlick, K; Deutsch, A; Beham-Schmid, C; Weiss, L; Gary, T; Neureiter, D; Klieser, E; Greil, R; Neumeister, P; Egle, A; Pichler, M;
Br J Cancer. 2016; 115(10):1264-1272
Full papers/articles (Journal)
A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.
Rawstron, AC; Fazi, C; Agathangelidis, A; Villamor, N; Letestu, R; Nomdedeu, J; Palacio, C; Stehlikova, O; Kreuzer, KA; Liptrot, S; O"Brien, D; de Tute, RM; Marinov, I; Hauwel, M; Spacek, M; Dobber, J; Kater, AP; Gambell, P; Soosapilla, A; Lozanski, G; Brachtl, G; Lin, K; Boysen, J; Hanson, C; Jorgensen, JL; Stetler-Stevenson, M; Yuan, C; Broome, HE; Rassenti, L; Craig, F; Delgado, J; Moreno, C; Bosch, F; Egle, A; Doubek, M; Pospisilova, S; Mulligan, S; Westerman, D; Sanders, CM; Emerson, R; Robins, HS; Kirsch, I; Shanafelt, T; Pettitt, A; Kipps, TJ; Wierda, WG; Cymbalista, F; Hallek, M; Hillmen, P; Montserrat, E; Ghia, P;
Leukemia. 2016; 30(4):929-936
Full papers/articles (Journal)
The clinical significance of fibrinogen plasma levels in patients with diffuse large B cell lymphoma.
Troppan, KT; Melchardt, T; Wenzl, K; Schlick, K; Deutsch, A; Bullock, MD; Reitz, D; Beham-Schmid, C; Weiss, L; Neureiter, D; Tränkenschuh, W; Greil, R; Neumeister, P; Egle, A; Pichler, M;
J Clin Pathol. 2016; 69(4):326-330
Full papers/articles (Journal)
CD1d expression on chronic lymphocytic leukemia B cells affects disease progression and induces T cell skewing in CD8 positive and CD4CD8 double negative T cells.
Zaborsky, N; Gassner, FJ; Asslaber, D; Reinthaler, P; Denk, U; Flenady, S; Hofbauer, JP; Danner, B; Rebhandl, S; Harrer, A; Geisberger, R; Greil, R; Egle, A;
Oncotarget. 2016; 7(31):4945-49469
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
CXCL12 ANTAGONISM BY THE L-RNA APTAMER OLAPTESED PEGOL IS EFFECTIVE AS A MOBILIZING AND THERAPEUTIC AGENT IN A MURINE CHRONIC LYMPHOCYTIC LEUKEMIA MODEL
Hinterseer, E; Hutterer, E; Krenn, PW; Reinthaler, P; Hopner, J; Hopfinger, M; Eulberg, D; Maasch, C; Kruschinski, A; Vater, A; Egle, A; Greil, R; Hartmann, TN
HAEMATOLOGICA. 2016; 101: 45-46.
Abstracts (Journal)
An elevated fibrinogen/CRP ratio predicts a remarkable survival advantage in patients with metastatic pancreatic cancer
Winder, T; Posch, F; Asamer, E; Stotz, M; Siebenhuner, A; Schlick, K; Magnes, T; Samaras, P; Szkandera, J; Clavien, PA; Neureiter, D; Greil, R; Pestalozzi, BC; Stoeger, H; Gerger, A; Egle, A; Pichler, M
ANN ONCOL. 2016; 27:
Abstracts (Journal)
2015
Journal Articles
CXCL12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: a role for CCL21.
Ganghammer, S; Hutterer, E; Hinterseer, E; Brachtl, G; Asslaber, D; Krenn, PW; Girbl, T; Berghammer, P; Geisberger, R; Egle, A; Zucchetto, A; Kruschinski, A; Gattei, V; Chigaev, A; Greil, R; Hartmann, TN;
Oncotarget. 2015; 6(14):12048-12060
Full papers/articles (Journal)
Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model.
Gassner, FJ; Zaborsky, N; Catakovic, K; Rebhandl, S; Huemer, M; Egle, A; Hartmann, TN; Greil, R; Geisberger, R;
Br J Haematol. 2015; 170(4):515-522
Full papers/articles (Journal)
Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera.
Gisslinger, H; Zagrijtschuk, O; Buxhofer-Ausch, V; Thaler, J; Schloegl, E; Gastl, GA; Wolf, D; Kralovics, R; Gisslinger, B; Strecker, K; Egle, A; Melchardt, T; Burgstaller, S; Willenbacher, E; Schalling, M; Them, NC; Kadlecova, P; Klade, C; Greil, R;
Blood. 2015; 126(15):1762-1769
Full papers/articles (Journal)
Anti-Hu Antibody Associated Paraneoplastic Cerebellar Degeneration in Head and Neck Cancer.
Huemer, F; Melchardt, T; Tränkenschuh, W; Neureiter, D; Moser, G; Magnes, T; Weiss, L; Schlattau, A; Hufnagl, C; Ricken, G; Höftberger, R; Greil, R; Egle, A;
BMC Cancer. 2015; 15:996
Case Reports
Factors Associated with Low-Level Viraemia and Virological Failure: Results from the Austrian HIV Cohort Study
Leierer, G; Grabmeier-Pfistershammer, K; Steuer, A; Geit, M; Sarcletti, M; Haas, B; Kanatschnig, M; Rappold, M; Zangerle, R; Ledergerber, B; Taylor, N
PLOS ONE. 2015; 10(11):
Full papers/articles (Journal)
– contribution as Studygroup-member
CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer.
Melchardt, T; Hufnagl, C; Magnes, T; Weiss, L; Hutarew, G; Neureiter, D; Schlattau, A; Moser, G; Gaggl, A; Tränkenschuh, W; Greil, R; Egle, A;
BMC Cancer. 2015; 15:725
Full papers/articles (Journal)
A modified scoring of the NCCN-IPI is more accurate in the elderly and is improved by albumin and β2 -microglobulin.
Melchardt, T; Troppan, K; Weiss, L; Hufnagl, C; Neureiter, D; Tränkenschuh, W; Hopfinger, G; Magnes, T; Deutsch, A; Neumeister, P; Hackl, H; Greil, R; Pichler, M; Egle, A;
Br J Haematol. 2015; 168(2):239-245
Full papers/articles (Journal)
Independent Prognostic Value of Serum Markers in Diffuse Large B-Cell Lymphoma in the Era of the NCCN-IPI.
Melchardt, T; Troppan, K; Weiss, L; Hufnagl, C; Neureiter, D; Tränkenschuh, W; Schlick, K; Huemer, F; Deutsch, A; Neumeister, P; Greil, R; Pichler, M; Egle, A;
J Natl Compr Canc Netw. 2015; 13(12):1501-1508
Full papers/articles (Journal)
Treatment of aggressive B-cell lymphoma in elderly patients: influence of single nucleotide polymorphisms affecting pharmacodynamics of chemotherapeutics.
Melchardt, T; Weiss, L; Hufnagl, C; Neureiter, D; Kemmerling, R; Morre, P; Boekstegers, A; Hopfinger, G; Auberger, J; Steinkirchner, S; Pleyer, L; Greil, R; Egle, A;
Leuk Lymphoma. 2015; 56(2):353-360
Full papers/articles (Journal)
Lessons from gain- and loss-of-function models of pro-survival Bcl2 family proteins: implications for targeted therapy.
Sochalska, M; Tuzlak, S; Egle, A; Villunger, A;
FEBS J. 2015; 282(5): 834-849.
Full papers/articles (Journal)
Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b.
Them, NC; Bagienski, K; Berg, T; Gisslinger, B; Schalling, M; Chen, D; Buxhofer-Ausch, V; Thaler, J; Schloegl, E; Gastl, GA; Wolf, D; Strecker, K; Egle, A; Melchardt, T; Burgstaller, S; Willenbacher, E; Zagrijtschuk, O; Klade, C; Greil, R; Gisslinger, H; Kralovics, R;
Am J Hematol. 2015; 90(4):288-294
Full papers/articles (Journal)
The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients.
Troppan, KT; Melchardt, T; Deutsch, A; Schlick, K; Stojakovic, T; Bullock, MD; Reitz, D; Beham-Schmid, C; Weiss, L; Neureiter, D; Wenzl, K; Greil, R; Neumeister, P; Egle, A; Pichler, M;
Eur J Haematol. 2015; 95(6):538-544
Full papers/articles (Journal)
B-cell receptor usage correlates with the sensitivity to CD40 stimulation and the occurrence of CD4+ T-cell clonality in chronic lymphocytic leukemia.
Zaborsky, N; Holler, C; Geisberger, R; Asslaber, D; Gassner, FJ; Egger, V; Piñón-Hofbauer, J; Kocher, T; Hartmann, TN; Greil, R; Egle, A;
Haematologica. 2015; 100(8):e307-e310
Letters
Conference papers, proceedings, abstracts
Four Weeks Administration Schedule of Ropeginterferon Alfa-2b (AOP2014/P1101) in Polycythemia Very Patients Allows Maintaining of Efficacy with Favorable Toxicity Profile in the Phase I/II Peginvera Stud
Buxhofer-Ausch, V; Gisslinger, H; Thaler, J; Schlogl, E; Gastl, G; Wolf, D; Kralovics, R; Gisslinger, B; Ban, S; Egle, A; Melchardt, T; Burgstaller, S; Willenbacher, E; Schalling, M; Krauth, MT; Them, NCC; Zorer, M; Ammann-Mwathi, O; Kadlecova, P; Zagrijtschuk, O; Klade, C; Greil, R
BLOOD. 2015; 126(23):
Abstracts (Journal)
MRD dynamics after chemoimmunotherapy induction treatment of CLL independently predict outcome: first analysis of a secondary endpoint from the international randomized AGMT-CLL8/a Mabtenance trial
Egle, A; Doubek, M; Stehlikova, O; Pleyer, L; Altenhofer, P; Melchardt, T; Smolej, L; Mihaylov, GG; Mikuskova, E; Mayer, J; Greil, R
LEUKEMIA LYMPHOMA. 2015; 56: 123-124.
Abstracts (Journal)
Long Term Efficacy and Safety Results and Analysis of Dose Correlations from the Phase I/II Peginvera Study of Ropeginterferon Alfa-2b, a Novel IFNa-2b, in Polycythemia Vera Patient
Gisslinger, H; Buxhofer-Ausch, V; Thaler, J; Schlogl, E; Gastl, G; Wolf, D; Schalling, M; Gisslinger, B; Ban, S; Egle, A; Melchardt, T; Burgstaller, S; Willenbacher, E; Krauth, MT; Them, NCC; Kralovics, R; Zorer, M; Ammann-Mwathi, O; Kadlecova, P; Zagrijtschuk, O; Klade, C; Greil, R
BLOOD. 2015; 126(23):
Abstracts (Journal)
Combination of age, ABC-type and intratumoral
T-regulator cells are a negative prognostic factors for
primary extranodal diffuse large B-cell lymphoma
Tränkenschuh, W; Kemmerling, R; Alinger, B; Melchardt, T; Egle, A; Kiesslich, T; Neureiter, D
PATHOLOGE . 2015; 36: 110-110.
Abstracts (Journal)
2014
Journal Articles
Old and new news in CLL: "It"s the pathway, stupid!".
Egle, A;
Blood. 2014; 124(7):989-990
Letters
Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia.
Gassner, FJ; Zaborsky, N; Neureiter, D; Huemer, M; Melchardt, T; Egle, A; Rebhandl, S; Catakovic, K; Hartmann, TN; Greil, R; Geisberger, R;
Haematologica. 2014; 99(5):67-69
Letters
Targeting proliferation of chronic lymphocytic leukemia (CLL) cells through KCa3.1 blockade.
Grössinger, EM; Weiss, L; Zierler, S; Rebhandl, S; Krenn, PW; Hinterseer, E; Schmölzer, J; Asslaber, D; Hainzl, S; Neureiter, D; Egle, A; Piñón-Hofbauer, J; Hartmann, TN; Greil, R; Kerschbaum, HH;
Leukemia. 2014; 28(4):954-958
Letters
Kasabach-Merritt phenomenon in hepatic angiosarcoma.
Habringer, S; Boekstegers, A; Weiss, L; Hopfinger, G; Meissnitzer, T; Melchardt, T; Egle, A; Greil, R;
Br J Haematol. 2014; 167(5):716-718
Letters
Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial.
Hopfinger, G; Nösslinger, T; Lang, A; Linkesch, W; Melchardt, T; Weiss, L; Egle, A; Greil, R;
Ann Hematol. 2014; 93(3):459-462
Full papers/articles (Journal)
How does lenalidomide target the chronic lymphocytic leukemia microenvironment?
Kater, AP; Tonino, SH; Egle, A; Ramsay, AG;
Blood. 2014; 124(14):2184-2189
Reviews
Liver toxicity during temozolomide chemotherapy caused by Chinese herbs.
Melchardt, T; Magnes, T; Weiss, L; Grundbichler, M; Strasser, M; Hufnagl, C; Moik, M; Greil, R; Egle, A;
BMC COMPLEM ALTERN M. 2014; 14: 115
Case Reports
Pleural decortication of a marginal zone lymphoma.
Melchardt, T; Weiss, L; Namberger, K; Pretsch, I; Hutter, J; Rettenbacher, L; Neureiter, D; Troch, M; Greil, R; Egle, A;
Ann Hematol. 2014; 93(7):1253-1254
Letters
Human immunodeficiency virus type 2 infections in Austria.
Taylor, N; Kern, JM; Prammer, W; Lang, A; Haas, B; Gisinger, M; Zangerle, R; Egle, A; Greil, R; Oberkofler, H; Eberle, J;
Wien Klin Wochenschr. 2014; 126(7-8):212-216
Full papers/articles (Journal)
C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients.
Troppan, KT; Schlick, K; Deutsch, A; Melchardt, T; Egle, A; Stojakovic, T; Beham-Schmid, C; Weiss, L; Neureiter, D; Wenzl, K; Greil, R; Neumeister, P; Pichler, M;
Br J Cancer. 2014; 111(1):55-60
Full papers/articles (Journal)
Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma.
Weiss, L; Melchardt, T; Habringer, S; Boekstegers, A; Hufnagl, C; Neureiter, D; Hopfinger, G; Greil, R; Egle, A;
Ann Oncol. 2014; 25(1):171-176
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
The integrin VLA-4 shows impaired CXCL12-induced inside-out activation in trisomy12 harboring chronic lymphocytic leukemia (CLL) cells
Ganghammer, S; Hutterer, E; Hinterseer, E; Brachtl, G; Asslaber, D; Krenn, PW; Girbl, T; Berghammer, P; Geisberger, R; Egle, A; Zucchetto, A; Gattei, V; Chigaev, A; Greil, R; Hartmann, TN
ONCOL RES TREAT. 2014; 37: 222-222.
Abstracts (Journal)
CLL INDUCES SEVERE SKEWING IN THE MYELOID COMPARTMENT IN PATIENTS AND IN THE TCL1 MOUSE MODEL
Hanna, B; McClanahan, F; Zaborsky, N; Durr, C; Gschwend, V; Stilgenbauer, S; Egle, A; Gribben, J; Lichter, P; Seiffert, M
HAEMATOLOGICA. 2014; 99: 228-229.
Abstracts (Journal)
Targeting Dysfunctional Myeloid Cells Delays Disease Development and Improves Immune Function in a CLL Mouse Model
Hanna, B; McClanahan, F; Zaborsky, N; Durr, C; Kalter, V; Egle, A; Gribben, JG; Lichter, P; Seiffert, M
BLOOD. 2014; 124(21):
Abstracts (Journal)
The Spiegelmer (R) NOX-A12 Mobilizes CLL Cells from Lymphoid Organs and Prevents Their Recirculation
Hinterseer, E; Girbl, T; Hutterer, E; Berghammer, P; Ganghammer, S; Sifft, EA; Pinon-Hofbauer, J; Egle, A; Kruschinski, A; Greil, R; Hartmann, TN
SCAND J IMMUNOL. 2014; 79(6): 468-469.
Abstracts (Journal)
Chronic Lymphocytic Leukaemia Cells with Trisomy 12 Home to the Bone Marrow in a CXCR4-Independent Manner
Hutterer, E; Ganghammer, S; Hinterseer, E; Brachtl, G; Asslaber, D; Krenn, P; Girbl, T; Berghammer, P; Geisberger, R; Egle, A; Zucchetto, A; Gattei, V; Chigaev, A; Greil, R; Hartmann, T
SCAND J IMMUNOL. 2014; 79(6): 468-468.
Abstracts (Journal)
Chronic Lymphocytic Leukaemia Cells with Trisomy 12 Home to the Bone Marrow in a CXCR4-Independent Manner
Hutterer, E; Ganghammer, S; Hinterseer, E; Brachtl, G; Asslaber, D; Krenn, P; Girbl, T; Berghammer, P; Geisberger, R; Egle, A; Zucchetto, A; Gattei, V; Chigaev, A; Greil, R; Hartmann, T
Chronic Lymphocytic Leukaemia Cells with Trisomy 12 Home to the Bone Marrow in a CXCR4-Independent Manner. 2014; 79(6): 424-478.-Scandinavian Society for Immunology
42nd Annual Meeting; 11.-14.06.2014; Reykjavik.
Abstracts (Journal)
A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study
Rawstron, A; Fazi, C; Villamor, N; Delgado, J; Letestu, R; Cymbalista, F; Palacio, C; Bosch, F; De Tute, RM; Liptrot, S; OxxxBrien, D; Spacek, M; Dobber, J; Kater, AP; Gambell, PC; Westerman, DA; Soosapilla, A; Mulligan, SP; Lozanski, G; Lin, K; Pettitt, AR; Brachtl, G; Egle, A; Williamson, DW; Sanders, CM; Robins, H; Boysen, J; Shanafelt, TD; Hanson, CA; Jorgensen, JL; Wierda, WG; Yuan, C; Stetler-Stevenson, M; Rassenti, L; Broome, HE; Kipps, TJ; Hauwel, M; Marinov, I; Craig, FE; Josep, N; Moreno, C; Stehlikova, O; Doubek, M; Pospisilova, S; Kreuzer, KA; Hallek, M; Hillmen, P; Montserrat, E; Ghia, P
BLOOD. 2014; 124(21):
Abstracts (Journal)
2013
Journal Articles
Mimicking the microenvironment in chronic lymphocytic leukaemia - where does the journey go?
Asslaber, D; Grössinger, EM; Girbl, T; Hofbauer, SW; Egle, A; Weiss, L; Greil, R; Hartmann, TN;
Br J Haematol. 2013; 160(5):711-714
Letters
Bid-ding for mercy: twisted killer in action.
Egle, A; Asslaber, D; Villunger, A; Pinon-Hofbauer, J;
Cell Death Differ. 2013; 20(7):847-849
Editorials
Protein kinase c-β-dependent activation of NF-κB in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in vivo.
Lutzny, G; Kocher, T; Schmidt-Supprian, M; Rudelius, M; Klein-Hitpass, L; Finch, AJ; Dürig, J; Wagner, M; Haferlach, C; Kohlmann, A; Schnittger, S; Seifert, M; Wanninger, S; Zaborsky, N; Oostendorp, R; Ruland, J; Leitges, M; Kuhnt, T; Schäfer, Y; Lampl, B; Peschel, C; Egle, A; Ringshausen, I;
Cancer Cell. 2013; 23(1):77-92
Full papers/articles (Journal)
[Autoimmune hemolysis accompanied by thrombopenia: consumption or myelodysplasia?].
Melchardt, T; Weiss, L; Egle, A;
Dtsch Med Wochenschr. 2013; 138(41): 2093-2095.
Case Reports
What’s new in Hodgkin’s lymphoma: ASH 2012 and more
Melchardt, T; Weiss, L; Greil, R; Egle, A;
Magazine of European Medical Oncology. 2013; Volume 6, Issue 3: 193-196.
Reviews
Viral infections and their management in patients with chronic lymphocytic leukemia.
Melchardt, T; Weiss, L; Greil, R; Egle, A;
Leuk Lymphoma. 2013; 54(8):1602-1613
Reviews
Complications of 5-azacytidine: Three cases of severe ischemic colitis in elderly patients with myelodysplastic syndrome.
Melchardt, T; Weiss, L; Pleyer, L; Steinkirchner, S; Auberger, J; Hopfinger, G; Greil, R; Egle, A;
Oncol Lett. 2013; 6(6):1756-1758
Full papers/articles (Journal)
Azacitidine in patients with WHO-defined AML - results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group.
Pleyer, L; Stauder, R; Burgstaller, S; Schreder, M; Tinchon, C; Pfeilstocker, M; Steinkirchner, S; Melchardt, T; Mitrovic, M; Girschikofsky, M; Lang, A; Krippl, P; Sliwa, T; Egle, A; Linkesch, W; Voskova, D; Angermann, H; Greil, R;
J HEMATOL ONCOL. 2013; 6: 32
Full papers/articles (Journal)
Cobas ampliprep/cobas TaqMan HIV-1 v2.0 assay: consequences at the cohort level.
Taylor, N; Grabmeier-Pfistershammer, K; Egle, A; Greil, R; Rieger, A; Ledergerber, B; Oberkofler, H;
PLoS One. 2013; 8(8):e74024
Full papers/articles (Journal)
Use of romiplostim allows for hepatitis C therapy in a HIV/HCV coinfected patient.
Taylor, N; Melchardt, T; Grundbichler, M; Strasser, M; Egle, A; Greil, R;
Ann Hematol. 2013; 92(7):1001-1002
Letters
p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa.
Valente, LJ; Gray, DH; Michalak, EM; Pinon-Hofbauer, J; Egle, A; Scott, CL; Janic, A; Strasser, A;
Cell Rep. 2013; 3(5):1339-1345
Full papers/articles (Journal)
Book chapters
Diagnostik und Therapie von diffus großzelligen Lymphomen (DLBCL)
Egle, A; Melchardt, T; Weiss, L;
In: Hopfinger, G; Greil, R (Hrsg.) editors(s). Aktuelle Diagnostik und Therapieoptionen bei aggressiven Lymphomen.. Bremen, London, Boston: UniMed Verlag; p. 26-35. (ISBN: 978-3-8374-1407-3)
Newspaper/magazine articles
Therapy with JAK 1/2 inhibitors for myelofibrosis
Romeder, F; Greil, R; Egle, A
memo - Magazine of European Medical Oncology, 2013/2. 2013.
2012
Journal Articles
Lysine residue at position 22 of the AID protein regulates its class switch activity.
Geisberger, R; Huemer, M; Gassner, FJ; Zaborsky, N; Egle, A; Greil, R;
PLoS One. 2012; 7(2):e30667
Full papers/articles (Journal)
Actinomycin D induces p53-independent cell death and prolongs survival in high-risk chronic lymphocytic leukemia.
Merkel, O; Wacht, N; Sifft, E; Melchardt, T; Hamacher, F; Kocher, T; Denk, U; Hofbauer, JP; Egle, A; Scheideler, M; Schlederer, M; Steurer, M; Kenner, L; Greil, R;
Leukemia. 2012; 26(12):2508-2516
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
T Cell Exhaustion Contributes to Immune Evasion in Chronic Lymphocytic Leukaemia
Gassner, FJ; Zaborsky, N; Neureiter, D; Huemer, M; Egle, A; Hartmann, TN; Greil, R; Geisberger, R
BLOOD. 2012; 120(21):
Abstracts (Journal)
AOP2014, a Novel Peg-Proline-Interferon Alpha-2b with Improved Pharmacokinetic Properties, Is Safe and Well Tolerated and Shows Promising Efficacy in Patients with Polycythemia Vera (PV)
Gisslinger, H; Kralovics, R; Gisslinger, B; Lechner, D; Buxhofer-Ausch, V; Strecker, K; Gastl, G; Willenbacher, E; Greil, R; Egle, A; Melchardt, T; Burgstaller, S; Schloegl, E; Tarmann, FJ; Zoerer, M; Klade, C; Zahriychuk, O; Thaler, J
BLOOD. 2012; 120(21):
Abstracts (Journal)
Protein Kinase C-beta Dependent Activation of NF-kappa B in Stromal Cells Is Indispensable for the Survival of Chronic Lymphocytic Leukemia B-Cells in Vivo
Lutzny, G; Kocher, T; Rudelius, M; Schmidt-Supprian, M; Klein-Hitpass, L; Durig, J; Oostendorp, RAJ; Peschel, C; Egle, A; Ringshausen, I
BLOOD. 2012; 120(21):
Abstracts (Journal)
Feasibility of anthracycline based treatment in unselected elderly DLBCL patients
Melchardt, T; Weiss, L; Hufnagl, C; Neureiter, D; Kemmerling, R; Hopfinger, G; Greil, R; Egle, A
ONKOLOGIE. 2012; 35: 86-87.
Abstracts (Journal)
Treatment of Aggressive B-Cell Lymphoma in the Elderly: The Influence of SNPs Affecting Pharmacodynamics Is Different Compared to Younger Patient
Melchardt, T; Weiss, L; Hufnagl, C; Neureiter, D; Kemmerling, R; Morre, P; Boekstegers, A; Hopfinger, G; Greil, R; Egle, A
BLOOD. 2012; 120(21):
Abstracts (Journal)
Complications of 5-azacytidine: Three cases of severe colitis in a single center cohort
Melchardt, T; Weiss, L; Pleyer, L; Steinkirchner, S; Greil, R; Egle, A
ONKOLOGIE. 2012; 35: 149-149.
Abstracts (Journal)
Upgraded Cobas TaqMan version 2: hidden consequences at cohort level
Taylor, N; Grabmeier-Pfistershammer, K; Oberkofler, H; Egle, A; Rieger, A; Ledergerber, B
J INT AIDS SOC. 2012; 15: 109-109.
Abstracts (Journal)
2011
Journal Articles
Treatment of invasive aspergillosis in cancer patients.
Auberger, J; Russ, G; Greil, R; Egle, A;
memo - Magazine of European Medical Oncology. 2011; 4 (4): 266-272.
Reviews
Differential bone marrow homing capacity of VLA-4 and CD38 high expressing chronic lymphocytic leukemia cells.
Brachtl, G; Sahakyan, K; Denk, U; Girbl, T; Alinger, B; Hofbauer, SW; Neureiter, D; Hofbauer, JP; Egle, A; Greil, R; Hartmann, TN;
PLoS One. 2011; 6(8):e23758
Full papers/articles (Journal)
Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia.
Gassner, FJ; Weiss, L; Geisberger, R; Hofbauer, JP; Egle, A; Hartmann, TN; Greil, R; Tinhofer, I;
Cancer Immunol Immunother. 2011; 60(1):7-85
Full papers/articles (Journal)
Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL.
Hofbauer, JP; Heyder, C; Denk, U; Kocher, T; Holler, C; Trapin, D; Asslaber, D; Tinhofer, I; Greil, R; Egle, A;
Leukemia. 2011; 25(9): 1452-1458.
Full papers/articles (Journal)
Clinical aspects of 2009 pandemic influenza A (H1N1) virus infection in Austria.
Poeppl, W; Hell, M; Herkner, H; Stoiser, B; Fritsche, G; Schurz-Bamieh, N; Poeppl, G; Gattringer, R; Jones, N; Maass, M; Egle, A; Burgmann, H;
Infection. 2011; 39(4):341-352
Full papers/articles (Journal)
Raltegravir in pregnancy: a case series presentation.
Taylor, N; Touzeau, V; Geit, M; Gisinger, M; Egle, A; Greil, R; Rieger, A; Zangerle, R;
Int J STD AIDS. 2011; 22(6): 358-360.
Case Reports
Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia.
Weiss, L; Melchardt, T; Egle, A; Grabmer, C; Greil, R; Tinhofer, I;
Cancer. 2011; 117(10):2163-2169
Full papers/articles (Journal)
Complete remission of Waldenström macroglobulinemia with azacitidine and rituximab.
Weiss, L; Melchardt, T; Neureiter, D; Kemmerling, R; Moshir, S; Pleyer, L; Greil, R; Egle, A;
J CLIN ONCOL. 2011; 29(24): e696-e698.
Case Reports
Conference papers, proceedings, abstracts
CLL CELLS INDUCE CLONAL T CELL SKEWING AND SUBSETSHIFTING IN THE MURINE TCL1 TRANSGENIC CHRONIC LYMPHOCYTIC LEUKEMIA MODEL
Egle, A; Pinon-Hofbauer, J; Heyder, C; Denk, U; Kocher, T; Holler, C; Trapin, D; Asslaber, D; Tinhofer, I; Greil, R
ANN ONCOL. 2011; 22: 144-144.
Abstracts (Journal)
A Combination of Fludarabine/Rituximab with Escalating Doses of Lenalidomide in Previously Untreated Chronic Lymphocytic Leukemia (CLL): The REVLIRIT CLL5 AGMT Phase I/II Study, Clinical and Exploratory Analyses of Induction Results
Egle, A; Steurer, M; Gassner, F; Geisberger, R; Melchardt, T; Weiss, L; Fridrik, MA; Thaler, J; Lang, A; Greil, R
BLOOD. 2011; 118(21): 135-136.
Abstracts (Journal)
Open-Label, Prospective, Multicentre, Phase I/II Study of AOP2014, a Novel PEG-Proline-Interferon Alpha-2b in Patients with Polycythemia Vera: Update from an Ongoing Study
Gisslinger, H; Kralovics, R; Schoder, R; Gisslinger, B; Buxhofer-Ausch, V; Strecker, K; Wolf, D; Willenbacher, E; Greil, R; Egle, A; Melchardt, T; Burgstaller, S; Tarmann, FJ; Wachter, C; Zahriycick, O; Thaler, J
BLOOD. 2011; 118(21): 762-762.
Abstracts (Journal)
Clonal Diversity of the T Cell Repertoire Predicts Disease Progression in Chronic Lymphocytic Leukaemia
Holler, C; Zaborsky, N; Hofbauer, JP; Kocher, T; Trapin, D; Asslaber, D; Greil, R; Egle, A
BLOOD. 2011; 118(21): 365-365.
Abstracts (Journal)
Activity of Azacitidine in 26 Unselected, Consecutive CMML Patients Included in the Austrian Azacitidine Registry (AAR) of the AGMT-Study Group
Pleyer, L; Stauder, R; Burgstaller, S; Schreder, M; Tinchon, C; Pfeilstocker, M; Steinkirchner, S; Melchardt, T; Mitrovic, M; Girschikofsky, M; Lang, A; Krippl, P; Egle, A; Sliwa, T; Linkesch, W; Fridrik, MA; Greil, R
BLOOD. 2011; 118(21): 747-747.
Abstracts (Journal)
Tumor load reduction and prolongation of overall-survival by actinomycin D in a murine model of high-risk chronic lymphocytic leukemia
Wacht, N; Sifft, E; Melchardt, T; Hamacher, F; Denk, U; Pinon-Hofbauer, J; Egle, A; Kocher, T; Steurer, M; Greil, R; Merkel, O
ONKOLOGIE. 2011; 34: 141-141.
Abstracts (Journal)
2010
Journal Articles
MicroRNAs as biomarkers for the diagnosis and prognosis of human cancer.
Asslaber, D; Pinon Hofbauer, J; Greil, R; Egle, A
Journal of nucleic acids investigation. 2010; Dec 1, 1(1): 76-80.
Full papers/articles (Journal)
microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia.
Asslaber, D; Piñón, JD; Seyfried, I; Desch, P; Stöcher, M; Tinhofer, I; Egle, A; Merkel, O; Greil, R;
Blood. 2010; 115(21):4191-4197
Full papers/articles (Journal)
Riding the 2-edged sword.
Egle, A;
Blood. 2010; 115(22): 4325-4326.
Letters
Apoptosis of leukocytes triggered by acute DNA damage promotes lymphoma formation.
Labi, V; Erlacher, M; Krumschnabel, G; Manzl, C; Tzankov, A; Pinon, J; Egle, A; Villunger, A;
Genes Dev. 2010; 24(15):1602-1607
Full papers/articles (Journal)
An uncommon cause of anaemia: Sheehan"s syndrome.
Melchardt, T; Namberger, K; Weiss, L; Egle, A; Faber, V; Greil, R;
WIEN KLIN WOCHENSCHR. 2010; 122(23-24): 717-719.
Case Reports
Interdependent regulation of p53 and miR-34a in chronic lymphocytic leukemia.
Merkel, O; Asslaber, D; Piñón, JD; Egle, A; Greil, R;
Cell Cycle. 2010; 9(14):2764-2768
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
Final Analysis of Induction Treatment with Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab In Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): The Chairos AGMT CLL4/Roche ML18434 Study
Egle, A; Weiss, L; Melchardt, T; Gunsilius, E; Petzer, AL; Fridrik, M; Lang, A; Krieger, O; Thaler, J; Greil, R
BLOOD. 2010; 116(21): 593-594.
Abstracts (Journal)
Deletion of Puma and p21(Waf1) In Mice Deactivates p53-Induced Cell Death and Cell Cycle Arrest, but Protects Mice From Irradiation-Induced Lymphomagenesis by a Mechanism Involving Hemopoietic Stem Cell Quiescence
Hofbauer, JP; Holler, C; Denk, U; Asslaber, D; Fastner, G; Labi, V; Villunger, A; Greil, R; Egle, A
BLOOD. 2010; 116(21): 45-46.
Abstracts (Journal)
Enzastaurin kills human CLL cells regardless of clinical risk profile, but fails to prolong life in a murine CLL model
Kocher, T; Pinon, HJ; Holler, C; Denk, U; Greil, R; Egle, A
ONKOLOGIE. 2010; 33: 40-40.
Abstracts (Journal)
Tumour suppression by BH3-only proteins, proapoptotic members of the Bcl-2 family
Villunger, A; Labi, V; Frenzel, A; Egle, A; Pinon, J
EJC SUPPL. 2010; 8(5): 1-1.
Abstracts (Journal)
2009
Journal Articles
Novel therapeutics approaches to chronic lymphocytic leukemia based on recent biological insights.
Hartmann, TN; Pleyer, L; Desch, P; Egle, A; Greil, R;
Discov Med. 2009; 8(42): 157-164.
Reviews
PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia.
Holler, C; Piñón, JD; Denk, U; Heyder, C; Hofbauer, S; Greil, R; Egle, A;
Blood. 2009; 113(12):2791-2794
Full papers/articles (Journal)
Molecular and cellular mechanisms of CLL: novel therapeutic approaches.
Pleyer, L; Egle, A; Hartmann, TN; Greil, R;
NAT REV CLIN ONCOL. 2009; 6(7): 405-418.
Reviews
Initial evaluation of the Roche COBAS TaqMan HIV-1 v2.0 assay for determining viral load in HIV-infected individuals.
Taylor, N; Schmid, I; Egle, A; Greil, R; Patsch, W; Oberkofler, H;
Antivir Ther. 2009; 14(8): 118-193.
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
FINAL RESULTS OF ORAL FLUDARABINE WITH CONCOMITANT SUBCUTANEOUS ALEMTUZUMAB IN RELAPSED/REFRACTORY B-CHRONIC LYMPHOCYTIC LEUKAEMIA (B-CLL): THE FLUSALEM STUDY
Egle, A; Melchardt, T; Pleyer, L; Tinhofer, I; Lang, A; Keil, F; Thaler, J; Gunsilius, E; Fridrik, M; Greil, R
HAEMATOL-HEMATOL J. 2009; 94: 140-140.
Abstracts (Journal)
The REVLIRIT CLL5 AGMT Study - a Phase I/II Trial Combining Fludarabine/Rituximab with Escalating Doses of Lenalidomide Followed by Rituximab/Lenalidomide in Untreated Chronic Lymphocytic Leukemia (CLL): Results of a Planned Interim Analysis
Egle, A; Steurer, M; Melchardt, T; Stoll, M; Greil, R
BLOOD. 2009; 114(22): 1341-1342.
Abstracts (Journal)
The Inverse Correlation of Regulatory T Cells and Time to Initial Treatment in Chronic Lymphocytic B-Cell Leukemia
Weiss, L; Melchardt, T; Grabmer, C; Egle, A; Tinhofer, I; Greil, R
BLOOD. 2009; 114(22): 510-510.
Abstracts (Journal)
2008
Journal Articles
Bim and Bmf in tissue homeostasis and malignant disease.
Piñon, JD; Labi, V; Egle, A; Villunger, A;
Oncogene. 2008; 27 Suppl 1:S41-S52
Reviews
Conference papers, proceedings, abstracts
T Cell Dynamics during the Pretumor and Tumor Phase in the Murine Tcll Transgenic Chronic Lymphocytic Leukemia Model
Egle, A; Pinon, JD; Heyder, C; Holler, C; Denk, U; Tinhofer, I; Greil, R
BLOOD. 2008; 112(11): 1078-1078.
Abstracts (Journal)
Minimal Residual Disease (MRD) and T/NK Cell Dynamics during Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab in Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): Riskfactor Stratification in the Chairos Study.
Egle, A; Weiss, L; Gassner, F; Russ, G; Pleyer, L; Gunsilius, E; Tinhofer, I; Thaler, J; Petzer, AL; Greil, R
BLOOD. 2008; 112(11): 1089-1089.
Abstracts (Journal)
2007
Conference papers, proceedings, abstracts
Planned first efficacy and safety analysis of de-intensified induction with fludarabine, cyclophosphamide plus rituximab (FCR) followed by fludarabine plus rituximab (FR) and remission maintenance therapy with rituximab in previously untreated B-chronic lymphocytic leukemia (B-CLL): The chairos study
Egle, A; Weiss, L; Russ, G; Thoedtmann, R; Pleyer, L; Gastl, G; Thaler, J; Petzer, A; Tinhofer, I; Greil, R
BLOOD. 2007; 110(11): 609A-609A.
Abstracts (Journal)
Book chapters
Follikuläres Lymphom.
Egle, A;
In: Greil, R (Ed.) editors(s). Lymphoproliferative Erkrankungen.. p. 93-107.
2006
Journal Articles
Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia.
Tinhofer, I; Rubenzer, G; Holler, C; Hofstaetter, E; Stoecher, M; Egle, A; Steurer, M; Greil, R;
Blood. 2006; 108(9):2950-2956
Full papers/articles (Journal)
The effect of IgVH mutational status on the induction of apoptosis by rituximab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: evidence from a clinical phase I/II trial.
Tinhofer, I; Steurer, M; Leitinger, G; Rumpold, H; Egle, A; Erdel, M; Greil, R;
Haematologica. 2006; 91(9): 1291-1293.
Letters
Conference papers, proceedings, abstracts
Planned first safety and efficacy analysis of oral fludarabine combined with subcutaneous alemtuzumab in 2(nd) line therapy of B-chronic lymphocytic leukaemia (B-CLL): The FLUSALEM study.
Egle, A; Tinhofer, I; Russ, G; Rass, C; Greil, R
BLOOD. 2006; 108(11): 336B-336B.
Abstracts (Journal)
2005
Journal Articles
Subversion of the Bcl-2 life/death switch in cancer development and therapy.
Adams, JM; Huang, DC; Strasser, A; Willis, S; Chen, L; Wei, A; van Delft, M; Fletcher, JI; Puthalakath, H; Kuroda, J; Michalak, EM; Kelly, PN; Bouillet, P; Villunger, A; O"Reilly, L; Bath, ML; Smith, DP; Egle, A; Harris, AW; Hinds, M; Colman, P; Cory, S;
Cold Spring Harb Symp Quant Biol. 2005; 70: 469-477.
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
Expression levels of CD38 in tumor cells and T-cells are of prognostic value in B-CLL
Tinhofer, I; Rubenzer, G; Egle, A; Greil, R
BLOOD. 2005; 106(11): 347A-347A.
Abstracts (Journal)
2004
Journal Articles
VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia.
Egle, A; Harris, AW; Bath, ML; O"Reilly, L; Cory, S;
Blood. 2004; 103(6):2276-2283
Full papers/articles (Journal)
Bim is a suppressor of Myc-induced mouse B cell leukemia.
Egle, A; Harris, AW; Bouillet, P; Cory, S;
P NATL ACAD SCI USA. 2004; 101(16): 6164-6169.
Full papers/articles (Journal)
Apaf-1 and caspase-9 do not act as tumor suppressors in myc-induced lymphomagenesis or mouse embryo fibroblast transformation.
Scott, CL; Schuler, M; Marsden, VS; Egle, A; Pellegrini, M; Nesic, D; Gerondakis, S; Nutt, SL; Green, DR; Strasser, A;
J CELL BIOL. 2004; 164(1): 8-96.
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
Making life and death decisions for cells
Cory, S; Egle, A; Bouillet, P; Puthalakath, H; Marsden, V; Hinds, M; Harris, A; Huang, D; Adams, J; Strasser, A; Day, C
FASEB J. 2004; 18(8): C225-C225.
Abstracts (Journal)
2003
Conference papers, proceedings, abstracts
Bim acts as a haploinsufficient and anti-leukemic tumor suppressor in Myc-induced lymphoma.
Egle, A; Bouillet, P; Harris, AW; Cory, S
BLOOD. 2003; 102(11): 135A-135A.
Abstracts (Journal)
VavP-Bc/2 transgenic mice develop clonal follicular lyraphoma preceded by germinal center hyperplasia.
Egle, A; Harris, AL; Bath, ML; OxxxReilly, L; Cory, S
BLOOD. 2003; 102(11): 67A-67A.
Abstracts (Journal)
2001
Journal Articles
TNF cytokine family: more BAFF-ling complexities.
Laâbi, Y; Egle, A; Strasser, A;
Curr Biol. 2001; 11(24): R1013-R1016.
Reviews
Conference papers, proceedings, abstracts
Stepping up treatment with Rituxan (R) (rituximab, Mabthera (R)) for CLL patients with advanced stage of disease relapsing after or refractory to conventional chemotherapy.
Greil, R; Steurer, M; Egle, A; Stauder, R; Anether, G; Ulmer, L; Tinhofer, I; Gastl, G
BLOOD. 2001; 98(11): 289B-290B.
Abstracts (Journal)
2000
Journal Articles
Analysis of Bcl-2 protein expression in chronic lymphocytic leukemia. A comparison of three semiquantitation techniques.
Marschitz, I; Tinhofer, I; Hittmair, A; Egle, A; Kos, M; Greil, R;
Am J Clin Pathol. 2000; 113(2): 21-29.
Full papers/articles (Journal)
Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma.
Tinhofer, I; Marschitz, I; Henn, T; Egle, A; Greil, R;
Blood. 2000; 95(2): 610-618.
Full papers/articles (Journal)
1998
Journal Articles
On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
Greil, R; Egle, A; Villunger, A;
Leuk Lymphoma. 1998; 31(5-6): 477-490.
Reviews
Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia.
Tinhofer, I; Marschitz, I; Kos, M; Henn, T; Egle, A; Villunger, A; Greil, R;
Blood. 1998; 91(11): 4273-4281.
Full papers/articles (Journal)
Functional granulocyte/macrophage colony stimulating factor receptor is constitutively expressed on neoplastic plasma cells and mediates tumour cell longevity.
Villunger, A; Egle, A; Kos, M; Egle, D; Tinhofer, I; Henn, T; Uberall, F; Maly, K; Greil, R;
Br J Haematol. 1998; 102(4): 1069-1080.
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
Inversion of CD4(+)/CD8(+) ratio in B chronic lymphocytic leukemia correlates with differential sensitivity of CD4(+) and CD8(+) T lymphocytes to the killing efficacy of Fas (APO-1/CD95) ligand(+) tumor cells.
Tinhofer, I; Marschitz, I; Kos, M; Henn, T; Egle, A; Villunger, A; Greil, R
BLOOD. 1998; 92(10): 271B-271B.
Abstracts (Journal)
1997
Journal Articles
Expression of Apo-1/Fas (CD95), Bcl-2, Bax and Bcl-x in myeloma cell lines: relationship between responsiveness to anti-Fas mab and p53 functional status.
Egle, A; Villunger, A; Marschitz, I; Kos, M; Hittmair, A; Lukas, P; Grünewald, K; Greil, R;
BRIT J HAEMATOL. 1997; 97(2): 41-28.
Full papers/articles (Journal)
The interleukin 1beta-converting enzyme inhibitor CrmA prevents Apo1/Fas- but not glucocorticoid-induced poly(ADP-ribose) polymerase cleavage and apoptosis in lymphoblastic leukemia cells.
Geley, S; Hartmann, BL; Kapelari, K; Egle, A; Villunger, A; Heidacher, D; Greil, R; Auer, B; Kofler, R;
FEBS Lett. 1997; 402(1): 36-40.
Full papers/articles (Journal)
Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells.
Villunger, A; Egle, A; Kos, M; Hartmann, BL; Geley, S; Kofler, R; Greil, R;
Cancer Res. 1997; 57(16): 3331-3334.
Full papers/articles (Journal)
Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance.
Villunger, A; Egle, A; Marschitz, I; Kos, M; Böck, G; Ludwig, H; Geley, S; Kofler, R; Greil, R;
BLOOD. 1997; 90(1): 12-20.
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
Fas (Apo-1/CD95) - Ligand expression on neoplastic plasma cells and its role for the expansion of the neoplastic clone.
Greil, R; Villunger, A; Egle, A; Marschitz, L; Kos, M; Bock, G; Ludwig, H; Geley, S; Kofler, R
BLOOD. 1997; 90(10): 1578-1578.
Abstracts (Journal)
1996
Journal Articles
IL-10 serum levels in B-cell chronic lymphocytic leukaemia.
Egle, A; Marschitz, I; Posch, B; Herold, M; Greil, R;
Br J Haematol. 1996; 94(1):211-212
Letters
Modulation of Apo-1/Fas (CD95)-induced programmed cell death in myeloma cells by interferon-alpha 2.
Egle, A; Villunger, A; Kos, M; Böck, G; Gruber, J; Auer, B; Greil, R;
Eur J Immunol. 1996; 26(12): 3119-3126.
Full papers/articles (Journal)
2",2"-Difluorodeoxycytidine (gemcitabine) induces apoptosis in myeloma cell lines resistant to steroids and 2-chlorodeoxyadenosine (2-CdA).
Gruber, J; Geisen, F; Sgonc, R; Egle, A; Villunger, A; Boeck, G; Konwalinka, G; Greil, R;
Stem Cells. 1996; 14(3):351-362
Full papers/articles (Journal)
Constituents of autocrine IL-6 loops in myeloma cell lines and their targeting for suppression of neoplastic growth by antibody strategies.
Villunger, A; Egle, A; Kos, M; Hittmair, A; Maly, K; Greil, R;
Int J Cancer. 1996; 65(4):498-505
Full papers/articles (Journal)
1991
Journal Articles
B-859-35, a new drug with anti-tumor activity reverses multi-drug resistance.
Hofmann, J; Ueberall, F; Egle, A; Grunicke, H;
Int J Cancer. 1991; 47(6):870-874
Full papers/articles (Journal)
Inhibition of cell proliferation, protein kinase C, and phorbol ester-induced fos expression by the dihydropyridine derivative B859-35.
Uberall, F; Maly, K; Egle, A; Doppler, W; Hofmann, J; Grunicke, HH;
Cancer Res. 1991; 51(21):5821-5825
Full papers/articles (Journal)